Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 97Other hematologic neoplasm 55Plasma cell 6Genitourinary 3Gastrointestinal 3Thoracic 2Myeloid 2NET 1Head & Neck 1Endocrine 1Dermatologic 1Classical hematology 1Breast 1

Conditions

Neuroendocrine Tumors 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

Everolimus 18lanreotide 7Octreotide 7pembrolizumab 6Sunitinib 6Magnetic Resonance Spectroscopy 5lutetium Lu 177 dotatate 4gallium Ga 68 dotatate 4cabozantinib 4Nivolumab 4Carboplatin 4telotristat ethyl 3pasireotide 3lenvatinib 3arginyllysine 3Temozolomide 3Specimen Handling 3Etoposide 3Erlotinib Hydrochloride 3Bevacizumab 3surufatinib 2pazopanib 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Sorafenib 2Phantoms, Imaging 2Paclitaxel 2Oxaliplatin 2Ipilimumab 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × ibrutinib × NET × Clear all
NCT02575300 2020-09-11

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
20 enrolled 11 charts
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡